Navigation Links
Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research

Bcl-2 Antagonist shown to be therapeutically effective in a mouse model of Chronic Lymphocytic Leukaemia

COPENHAGEN, 18 April 2007 - Santaris Pharma, the Danish biopharmaceutical company developing RNAi drugs, yesterday presented encouraging data at the American Association for Cancer Research Annual Meeting in Los Angeles, showing that SPC2996, the Company's RNA Antagonist of Bcl-2, is therapeutically active in a preclinical model of human Chronic Lymphocytic Leukaemia (CLL).

In collaboration with scientists at the University of Duisberg-Essen in Germany, Santaris researchers reported that white blood cells obtained from CLL patient peripheral blood can be transplanted into immunodeficient mice and reliable engraftment of human CLL cells achieved in the spleen, resulting in focal aggregates of B-lymphocytes carrying surface markers characteristic of CLL cancer cells.

SPC2996 was tested for anti-leukaemic activity over two weeks in this model starting two weeks after transplantation and compared for efficacy with multiple doses of fludarabine, a standard chemotherapy for CLL, as well as a negative control oligonucleotide drug similar to but of different sequence from SPC2996. Therapy with SPC2996 resulted in a 54% reduction (p=0.043) in the number of CLL cells which could be recovered from the spleens of the treated transplanted animals compared to animals not receiving therapy. Fludarabine was also effective in the model whereas the negative control drug was not.

This is the first time that primary CLL cells taken from patient blood have been successfully transplanted and shown long term splenic engraftment in an animal model. The model appears to be validated by the efficacy of the fludarabine in clearing engrafted human CLL cells. The demonstration that single agent therapy with SPC2996, a non-chemotoxic agent inhibiting Bcl-2 expression, also clears CLL cells from splenic engraft
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:3/27/2015)... March 27, 2015 RnRMarketResearch.com ... therapeutic market research report of 52 pages with ... business intelligence library. The report "Visceral ... the therapeutic development for Visceral Pain, complete with ... drug target, mechanism of action (MoA), route of ...
(Date:3/27/2015)... YORK , March 27, 2015 /PRNewswire/ ... the leading source of health information, today ... the new National Action Plan for ... President Obama emphasized the urgency and importance ... on national and global health.    ...
(Date:3/26/2015)... PASADENA, Calif. , March 26, 2015 ... San Gabriel Valley to perform transcatheter aortic valve replacement ... TAVR procedure is a revolutionary new way to replace ... use of a heart lung machine. The ... heart team led by Azhil ( Alex) Durairaj , ...
Breaking Medicine Technology:Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2
(Date:3/27/2015)... Canadian Cannabis Clinics ( http://www.cannabisclinics.ca ), ... of medical cannabis as a treatment for patients ... clinics dedicated to providing access to safe medical ... patients searching for medical marijuana treatment in legal ... sub domain for Canada. , With the ...
(Date:3/27/2015)... The Florida Center for Brain Tumor ... (ABC2), awarded $350,000 to support brain cancer research at ... Research Institute and H. Lee Moffitt Cancer Center and ... clear development path and potential to provide meaningful improvements ... , The awards fund research in areas on ...
(Date:3/26/2015)... Let’s not lose focus of why ... today’s traffic magnets. Three out of 4 consumers choose ... produce department, according to a Packaged Facts survey. Produce ... looking to add more fruits and vegetables to their ... is April 2. As featured in the Chase’s Calendar ...
(Date:3/26/2015)... The American College of Traditional Chinese Medicine announces several ... DAOM Program as well as Marketing Basics for Healers & ... by Dr. Carla Wilson, who will give an overview of ... prepare for the spring quarter. The webinar will be from ... and April 3. Attendees can log in from work or ...
(Date:3/26/2015)... Building off their success and ... the Cardiometabolic Risk Summit and ... are proud to announce a pioneering professional ... interdisciplinary program , which ultimately grants a Certified ... physicians, nurse practitioners, physician assistants, registered dietitians, and ...
Breaking Medicine News(10 mins):Health News:Canadian Cannabis Clinics (CCC) to Join the Canada.MarijuanaDoctors.com Network 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 3Health News:ACTCM Announces Upcoming Webinars 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3
... A study finds that sleep deprivation can adversely affect ... the expectation of gains and making light of ... understand the neural underpinnings of risky decision making under ... Duke University studied healthy volunteers as they underwent functional ...
... older women - those 80 or older - have the greatest ... today. ,Worryingly, the research also found that 56 per ... cancer risk. ,The strongest risk factor for breast cancer ... her risk. About one in 70 women will develop breast cancer ...
... risk of cancer; a Danish study conducted amongst 28,000 ... ,Danish medical records were analyzed to monitor ... among the utility workers for 23years. This was done ... and its effects. ,The researchers did not ...
... definite link between pregnancy, migraine and stroke, US researchers ... one. ,In fact, Cheryl Bushnell, assistant professor ... Disease in Durham, explained that pregnant women who suffered ... than pregnant women who did not suffer migraine. ...
... talked about testosterone cream for enhancing sexual desire in female ... conducted by Mayo clinic has shown. ... As an extension to a previous study which pointed a ... with sufficient estrogen levels, this new study was conducted on ...
... one out of depression. But its potential to drive ... ,Now the U.S. Food and Drug Administration (FDA) ... the existing black box warning on their products' labeling ... and behavior, in young adults ages 18 to 24 ...
Cached Medicine News:Health News:Sleep Deprivation can Affect Competent Decision-making 2Health News:Women Unaware of When Breast Cancer Risk is Greatest 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3
... is a premium agarose used for isolating ... agarose produces clear sharp bands, with no ... of UltraClean Forensic Agarose is tested and ... RNase activity and DNA contamination. ...
... is specifically formulated for high resolution of ... bp. This standard melting temperature agarose can ... 10 bp difference in size. UltraPure™ ... structure for better handling and improved clarity ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
... solid. Highly purified non-ionic fraction of agar. ... very low concentrations. Can be mounted on ... films are elastic and durable and show ... either protein or lipoprotein dyes. Contaminants: ...
Medicine Products: